TR201807543A2 - Pharmaceutical Composition for the Treatment of Infectious Foot Diseases of Animals - Google Patents
Pharmaceutical Composition for the Treatment of Infectious Foot Diseases of Animals Download PDFInfo
- Publication number
- TR201807543A2 TR201807543A2 TR2018/07543A TR201807543A TR201807543A2 TR 201807543 A2 TR201807543 A2 TR 201807543A2 TR 2018/07543 A TR2018/07543 A TR 2018/07543A TR 201807543 A TR201807543 A TR 201807543A TR 201807543 A2 TR201807543 A2 TR 201807543A2
- Authority
- TR
- Turkey
- Prior art keywords
- feature
- pharmaceutical composition
- weight
- composition according
- individuals
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 56
- 241001465754 Metazoa Species 0.000 title claims description 49
- 208000014770 Foot disease Diseases 0.000 title claims description 47
- 208000015181 infectious disease Diseases 0.000 title claims description 39
- 230000002458 infectious effect Effects 0.000 title claims description 31
- 206010052428 Wound Diseases 0.000 claims abstract description 33
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 33
- 208000025865 Ulcer Diseases 0.000 claims abstract description 16
- 238000007906 compression Methods 0.000 claims abstract description 11
- 230000006835 compression Effects 0.000 claims abstract description 11
- 230000003902 lesion Effects 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- 241000283690 Bos taurus Species 0.000 claims description 24
- 208000006413 Digital Dermatitis Diseases 0.000 claims description 24
- 208000023867 digital dermatitis in cattle Diseases 0.000 claims description 24
- 201000004624 Dermatitis Diseases 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 22
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 20
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 20
- 230000002421 anti-septic effect Effects 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 16
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 229960005070 ascorbic acid Drugs 0.000 claims description 12
- 235000010323 ascorbic acid Nutrition 0.000 claims description 12
- 239000011668 ascorbic acid Substances 0.000 claims description 12
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 12
- 229960004099 azithromycin Drugs 0.000 claims description 12
- 229910052750 molybdenum Inorganic materials 0.000 claims description 12
- 239000011733 molybdenum Substances 0.000 claims description 12
- 229910052711 selenium Inorganic materials 0.000 claims description 12
- 239000011669 selenium Substances 0.000 claims description 12
- 239000002562 thickening agent Substances 0.000 claims description 12
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 10
- 229960004308 acetylcysteine Drugs 0.000 claims description 10
- 230000003115 biocidal effect Effects 0.000 claims description 10
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 10
- 239000004327 boric acid Substances 0.000 claims description 10
- 239000006172 buffering agent Substances 0.000 claims description 10
- 229960000541 cetyl alcohol Drugs 0.000 claims description 10
- 239000011777 magnesium Substances 0.000 claims description 10
- 229910052749 magnesium Inorganic materials 0.000 claims description 10
- 239000002674 ointment Substances 0.000 claims description 10
- 239000011787 zinc oxide Substances 0.000 claims description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- 229960004926 chlorobutanol Drugs 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 8
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 8
- 239000011707 mineral Substances 0.000 claims description 8
- 235000010755 mineral Nutrition 0.000 claims description 8
- 235000019271 petrolatum Nutrition 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 206010040872 skin infection Diseases 0.000 claims description 8
- 241000283707 Capra Species 0.000 claims description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 206010017564 Fusobacterium infections Diseases 0.000 claims description 6
- 206010028846 Necrobacillosis Diseases 0.000 claims description 6
- 241001494479 Pecora Species 0.000 claims description 6
- 239000004264 Petrolatum Substances 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- 229910052804 chromium Inorganic materials 0.000 claims description 6
- 239000011651 chromium Substances 0.000 claims description 6
- 229910052802 copper Inorganic materials 0.000 claims description 6
- 239000010949 copper Substances 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 229940066842 petrolatum Drugs 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 150000004781 alginic acids Chemical class 0.000 claims description 4
- -1 alpha tocapherol Chemical compound 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 235000010407 ammonium alginate Nutrition 0.000 claims description 4
- 239000000728 ammonium alginate Substances 0.000 claims description 4
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 235000010410 calcium alginate Nutrition 0.000 claims description 4
- 239000000648 calcium alginate Substances 0.000 claims description 4
- 229960002681 calcium alginate Drugs 0.000 claims description 4
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 4
- 239000007765 cera alba Substances 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 229940014259 gelatin Drugs 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 235000010408 potassium alginate Nutrition 0.000 claims description 4
- 239000000737 potassium alginate Substances 0.000 claims description 4
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 229910052726 zirconium Inorganic materials 0.000 claims description 4
- 229960000292 pectin Drugs 0.000 claims description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 2
- 229910052748 manganese Inorganic materials 0.000 claims 2
- 239000011572 manganese Substances 0.000 claims 2
- 235000013336 milk Nutrition 0.000 abstract description 15
- 239000008267 milk Substances 0.000 abstract description 15
- 210000004080 milk Anatomy 0.000 abstract description 15
- 235000013372 meat Nutrition 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 231100000397 ulcer Toxicity 0.000 abstract description 5
- 239000003814 drug Substances 0.000 description 28
- 229940079593 drug Drugs 0.000 description 24
- 230000035876 healing Effects 0.000 description 18
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 239000002994 raw material Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000002203 pretreatment Methods 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 229940124350 antibacterial drug Drugs 0.000 description 6
- 230000002146 bilateral effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 229910000365 copper sulfate Inorganic materials 0.000 description 4
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 4
- 208000010801 foot rot Diseases 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 208000004396 mastitis Diseases 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940031955 anhydrous lanolin Drugs 0.000 description 2
- 229960002645 boric acid Drugs 0.000 description 2
- 235000010338 boric acid Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000002390 cell membrane structure Anatomy 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229960003760 florfenicol Drugs 0.000 description 2
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 2
- 229960000588 flunixin Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 208000030175 lameness Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 229960001407 sodium bicarbonate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical class CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229960001296 zinc oxide Drugs 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Buluş özellikle, çiftlik hayvanlarında görülen interdigital nekrobasillozis (foot rot), interdigital dermatitis, digital dermatitis, ökçe lezyonu gibi enfeksiyoz ayak hastalıkları başta olmak üzere, hayvanlarda görülen her tür dekübital yaralar, ülseratif yaralar, kompresyon yaraları ve deri enfeksiyonlarının lokal tedavisine yönelik, lezyon alanında tutunabilecek, emilebilen, lokal etkisi yüksek, ette ve sütte kalıntı oluşturmayacak, kolay uygulanabilir bir farmasötik kompozisyon ile ilgilidir.In particular, the invention is directed to the treatment of all types of decubital wounds, ulcerative wounds, compression wounds, and ulcers The present invention relates to an easily administrable pharmaceutical composition which can be adsorbed, absorbable, has a high local effect and does not form residue in meat and milk.
Description
TARIFNAME Hayvanlarin Enfeksiyöz Ayak Hastaliklarinin Tedavisine Yönelik Farmasötik Kompozisyon Teknik Alan Bulus, çiftlik hayvanlarinin enfeksiyöz ayak hastaliklarin tedavisine yönelik farmasötik kompozisyon ile ilgilidir. DESCRIPTION Pharmaceutical for the Treatment of Infectious Foot Diseases of Animals Composition Technical Area The invention is a pharmaceutical product for the treatment of infectious foot diseases of farm animals. It's about composition.
Bulus özellikle, çiftlik hayvanlarinda görülen interdigital nekrobasillozis (foot rot), interdigital dermatitis, digital dermatitis, ökçe Iezyonu gibi enfeksiyöz ayak hastaliklari basta olmak üzere, hayvanlarda görülen her tür dekübital yaralar, ülseratif yaralar, kompresyon yaralari ve deri enfeksiyonlarinin lokal tedavisine yönelik, lezyon alaninda tutunabilecek, emilebilen, lokal etkisi yüksek, ette ve sütte kalinti olusturmayacak, kolay uygulanabilir bir farmasötik kompozisyon ile ilgilidir. The invention is particularly focused on interdigital necrobacillosis (foot rot), interdigital especially infectious foot diseases such as dermatitis, digital dermatitis, heel lesion all kinds of decubital wounds, ulcerative wounds, compression wounds in animals, and for the local treatment of skin infections, can be adhered to the lesion area, can be absorbed, It is an easily applicable pharmaceutical with high local effect, which will not leave residue in meat and milk. It's about composition.
Teknigin Bilinen Durumu Sigircilik isletmelerinde en büyük masraflarin basinda yem giderleri ve hastaliklarla mücadele gelir. Bu hastaliklarda üreme problemleri, mastitis problemleri ve ayak hastaliklaridir. Hayvanlarin sürüden istem disi olarak atilmalarina yol açan en önemli problemlerin basinda da genelde ayak ve tirnak problemleri ile ortaya çikan topalliklar gelmektedir. Ayak hastaliklariyla mücadelede en etkin yol düzenli tirnak kontrolü, tirnak bakimi ve olusan hastaliklarin etkin tedavisidir. State of the Art At the beginning of the biggest expenses in the livestock enterprises are the feed expenses and diseases. the fight comes. In these diseases, reproductive problems, mastitis problems and foot problems. are diseases. The most important cause of involuntary expulsion of animals from the herd. lameness, which usually occurs with foot and nail problems, is at the beginning of the problems. is coming. The most effective way to combat foot diseases is regular nail control. care and effective treatment of the diseases that occur.
Ayak ve tirnaklardaki problemler tedavi edilmedikçe hayvanlara sikinti vermekte, onlarin yürümelerine, yem yemelerine, merada gezinmelerine mani olmakta ve sonuçta hayvanlarin süt, et ve döl verimlerinin azalmasina, sürü disina çikarilmalarina hatta ölümlerine dahi neden olabilmektedir. Problems in feet and nails cause distress to animals unless they are treated. It prevents them from walking, eating, walking in the pasture, and ultimately the animals decrease in milk, meat and progeny yields, exclusion from the herd and even death. may cause.
Sigirlarda görülen önemli ayak hastaliklari Iaminitis sendrom, Iaminitis ile iliskili tirnak kapsülü hastaliklari (taban ülseri, beyaz çizgi hastaligi, tirnak ucu ülseri, ökçe kornusunun erozyonu) ve enfeksiyöz ayak hastaliklari (interdigital nekrobasillozis (foot rot), interdigital dermatitis, digital dermatitis, ökçe Iezyonu) olarak siniflandirilmaktadir. Important foot diseases in cattle Iaminitis syndrome, nail associated with Iaminitis capsule diseases (floor ulcer, white line disease, nail tip ulcer, heel cornea erosion) and infectious foot diseases (interdigital necrobacillosis (foot rot), interdigital dermatitis, digital dermatitis, heel lesion).
Günümüzde hayvanlarin ayak hastaliklarinda kullanilan medikal uygulamalar içerisinde lokal ve sistemik etkili çesitli ilaçlarin kullanimi ile rejyonal intravenöz antibakteriyel ilaç uygulamalari bulunmaktadir. Lokal uygulamalar antiseptik ve antibakteriyel içeren solüsyon, TARIFNAME Hayvanlarin Enfeksiyöz Ayak Hastaliklarinin Tedavisine Yönelik Farmasötik Kompozisyon Teknik Alan Bulus, çiftlik hayvanlarinin enfeksiyöz ayak hastaliklarin tedavisine yönelik farmasötik kompozisyon ile ilgilidir. Today, among the medical applications used in the foot diseases of animals, local and regional intravenous antibacterial drug with the use of various drugs with systemic effects. has applications. Local applications containing antiseptic and antibacterial solution, DESCRIPTION Pharmaceutical for the Treatment of Infectious Foot Diseases of Animals Composition Technical Area The invention is a pharmaceutical product for the treatment of infectious foot diseases of farm animals. It's about composition.
Bulus özellikle, çiftlik hayvanlarinda görülen interdigital nekrobasillozis (foot rot), interdigital dermatitis, digital dermatitis, ökçe Iezyonu gibi enfeksiyöz ayak hastaliklari basta olmak üzere, hayvanlarda görülen her tür dekübital yaralar, ülseratif yaralar, kompresyon yaralari ve deri enfeksiyonlarinin lokal tedavisine yönelik, lezyon alaninda tutunabilecek, emilebilen, lokal etkisi yüksek, ette ve sütte kalinti olusturmayacak, kolay uygulanabilir bir farmasötik kompozisyon ile ilgilidir. The invention is particularly focused on interdigital necrobacillosis (foot rot), interdigital especially infectious foot diseases such as dermatitis, digital dermatitis, heel lesion all kinds of decubital wounds, ulcerative wounds, compression wounds in animals, and for the local treatment of skin infections, can be adhered to the lesion area, can be absorbed, It is an easily applicable pharmaceutical with high local effect, which will not leave residue in meat and milk. It's about composition.
Teknigin Bilinen Durumu Sigircilik isletmelerinde en büyük masraflarin basinda yem giderleri ve hastaliklarla mücadele gelir. Bu hastaliklarda üreme problemleri, mastitis problemleri ve ayak hastaliklaridir. Hayvanlarin sürüden istem disi olarak atilmalarina yol açan en önemli problemlerin basinda da genelde ayak ve tirnak problemleri ile ortaya çikan topalliklar gelmektedir. Ayak hastaliklariyla mücadelede en etkin yol düzenli tirnak kontrolü, tirnak bakimi ve olusan hastaliklarin etkin tedavisidir. State of the Art At the beginning of the biggest expenses in the livestock enterprises are the feed expenses and diseases. the fight comes. In these diseases, reproductive problems, mastitis problems and foot problems. are diseases. The most important cause of involuntary expulsion of animals from the herd. lameness, which usually occurs with foot and nail problems, is at the beginning of the problems. is coming. The most effective way to combat foot diseases is regular nail control. care and effective treatment of the diseases that occur.
Ayak ve tirnaklardaki problemler tedavi edilmedikçe hayvanlara sikinti vermekte, onlarin yürümelerine, yem yemelerine, merada gezinmelerine mani olmakta ve sonuçta hayvanlarin süt, et ve döl verimlerinin azalmasina, sürü disina çikarilmalarina hatta ölümlerine dahi neden olabilmektedir. Problems in feet and nails cause distress to animals unless they are treated. It prevents them from walking, eating, walking in the pasture, and ultimately the animals decrease in milk, meat and progeny yields, exclusion from the herd and even death. may cause.
Sigirlarda görülen önemli ayak hastaliklari Iaminitis sendrom, Iaminitis ile iliskili tirnak kapsülü hastaliklari (taban ülseri, beyaz çizgi hastaligi, tirnak ucu ülseri, ökçe kornusunun erozyonu) ve enfeksiyöz ayak hastaliklari (interdigital nekrobasillozis (foot rot), interdigital dermatitis, digital dermatitis, ökçe Iezyonu) olarak siniflandirilmaktadir. Important foot diseases in cattle Iaminitis syndrome, nail associated with Iaminitis capsule diseases (floor ulcer, white line disease, nail tip ulcer, heel cornea erosion) and infectious foot diseases (interdigital necrobacillosis (foot rot), interdigital dermatitis, digital dermatitis, heel lesion).
Günümüzde hayvanlarin ayak hastaliklarinda kullanilan medikal uygulamalar içerisinde lokal ve sistemik etkili çesitli ilaçlarin kullanimi ile rejyonal intravenöz antibakteriyel ilaç uygulamalari bulunmaktadir. Lokal uygulamalar antiseptik ve antibakteriyel içeren solüsyon, toz ve pomat seklinde ilaçlari içermektedir. Sistemik etkili ilaçlar ise uzun süreli ve genis spektrumlu antibiyotiklerdir. Rejyonal olarak intravenöz uygulanan antibakteriyel ilaçlar ise suda eriyen antibiyotiklerden olusmaktadir. Today, among the medical applications used in the foot diseases of animals, local and regional intravenous antibacterial drug with the use of various drugs with systemic effects. has applications. Local applications containing antiseptic and antibacterial solution, It contains drugs in the form of powder and pomade. Systemic-acting drugs are long-term and extensive. spectrum antibiotics. Antibacterial drugs administered intravenously regionally It consists of water-soluble antibiotics.
Hayvanlarin ayak hastaliklarinin etkin tedavisinde eksizyon ve küretaj yapilmasini takiben lokal ilaç uygulamalarinin basarisi sistemik ilaç kullanimina kiyasla daha yüksektir. Çiftlik hayvanlarinda sistemik etkili ilaçlarin kullaniminda sütte ve ette toplum sagligina zararli kalinti riski bulunmaktadir. Rejyonal olarak intravenöz uygulanilan antibakteriyel ilaçlarin ise lokal olarak kullanilacak toz solüsyon ya da pomatlara göre uygulama zorlugunun bulunmasi ve tecrübe gerektirmesi pratikligini sinirlamaktadir. Following excision and curettage in the effective treatment of animal foot diseases The success of local drug applications is higher than systemic drug use. Farm Harmful to public health in milk and meat in the use of systemic drugs in animals there is a risk of residue. Antibacterial drugs administered regionally intravenously Difficulty in application compared to powder solutions or pomades to be used locally and the need for experience limits its practicality.
Sahada sigirlarin ayak hastaliklarinin tedavisinde lokal olarak kullanilan medikaller siklikla beseri antibakteriyel deri pomatlari, mastitis tedavisinde kullanilan meme içi preparatlar, antiseptik etkili çesitli toz ve solüsyonlardan olusmaktadir. Enfeksiyöz ayak hastaliklarinin tedavisinde kullanilan antiseptik etkili ilaçlar problemin çözümünde yetersiz kalmakta ve siklikla nükslerle sonuçlanmaktadir. Degisik antibakteriyel deri pomatlari ve meme içi kullanilan preparatlar ile sagaltima alinan yanitlarda standart degildir. Medicines used locally in the treatment of foot diseases of cattle in the field are often human antibacterial skin pomades, intramammary preparations used in the treatment of mastitis, It consists of various powders and solutions with antiseptic effect. Infectious foot diseases The antiseptic drugs used in the treatment are insufficient to solve the problem and often results in relapses. Various antibacterial skin pomades and intramammary pomades The preparations used and the responses to the treatment are not standard.
Konu ile ilgili, mevcut teknikte literatür taramasi yapildiginda rastlanilan basvurulardan biri TR2008/00666 basvuru numarali, 'Sigir ve domuzlarda enfeksiyonlari tedavi etmek için bilesimler ve usul, baslikli ulusal patent basvurusudur. Söz konusu basvuruda bulus, sigir ve domuzlarda görülen bulasici hastaliklarin tedavisinde ve önlenmesinde kullanimi için Fluniksin gibi bir steroid olmayan enflamasyon önleyici ilaç ile florfenikol gibi bir florlanmis kloroamfenikol veya tiamfenikol türevi antibiyotigi biraraya getiren yeni formülasyonlari içermektedir. One of the references found when a literature review is made on the subject in the current technique. Application number TR2008/00666, 'For the treatment of infections in cattle and pigs compositions and method is a national patent application entitled. In the application in question, invention, sigir and for use in the treatment and prevention of infectious diseases in pigs. A non-steroidal anti-inflammatory drug such as flunixin and a fluorinated drug such as florfenicol New formulations combining chloroamphenicol or thiamphenicol derivative antibiotic contains.
Diger bir basvuru ise CN “Büyükbas ayak hastaliginin tedavisi için kombine ilaç ve hazirlama yöntemi› baslikli Çin patent basvurusunda bulus, toz formunda olup, etilendiamin dihidroiyodür ve bakir sülfatin 1:2-223'Iük bir kütle oraninda karistirilmasiyla olusan kombine ilaci içerir. Etilendiamin dihidroiyodür ve bakir sülfatin reaksiyona girmesiyle ortaya çikan serbest elementel iyot patojenlerin hücre zari yapisini bozarak enfeksiyonu önleyebilir. Another application is CN “Combination for the treatment of cattle foot disease. The invention in the Chinese patent application titled “medicine and preparation method” is in powder form, by mixing ethylenediamine dihydroiodide and copper sulfate in a mass ratio of 1:2-223. Contains the combined drug. By reacting ethylenediamine dihydroiodide and copper sulfate The resulting free elemental iodine disrupts the cell membrane structure of pathogens and causes infection. can prevent.
Konu ile ilgili patentler incelendiginde çiftlik hayvanlarinda enfeksiyöz ayak hastaliklarinin tedavisinde kullanilmaya yönelik olarak lezyon alaninda tutunabilecek, emilebilen, lokal etkisi yüksek, ette ve sütte kalinti olusturmayacak, kolay uygulanabilir bir farmasötik kompozisyona olan gereksinim varligi ortaya çikmaktadir. toz ve pomat seklinde ilaçlari içermektedir. Sistemik etkili ilaçlar ise uzun süreli ve genis spektrumlu antibiyotiklerdir. Rejyonal olarak intravenöz uygulanan antibakteriyel ilaçlar ise suda eriyen antibiyotiklerden olusmaktadir. When the patents on the subject are examined, it is seen that infectious foot diseases in farm animals Absorbable, local effect that can be adhered to the lesion area for use in the treatment of It has a high, easy to apply pharmaceutical composition that will not form residues in meat and milk. the existence of need emerges. It contains drugs in the form of powder and pomade. Systemic-acting drugs are long-term and extensive. spectrum antibiotics. Antibacterial drugs administered intravenously regionally It consists of water-soluble antibiotics.
Hayvanlarin ayak hastaliklarinin etkin tedavisinde eksizyon ve küretaj yapilmasini takiben lokal ilaç uygulamalarinin basarisi sistemik ilaç kullanimina kiyasla daha yüksektir. Çiftlik hayvanlarinda sistemik etkili ilaçlarin kullaniminda sütte ve ette toplum sagligina zararli kalinti riski bulunmaktadir. Rejyonal olarak intravenöz uygulanilan antibakteriyel ilaçlarin ise lokal olarak kullanilacak toz solüsyon ya da pomatlara göre uygulama zorlugunun bulunmasi ve tecrübe gerektirmesi pratikligini sinirlamaktadir. Following excision and curettage in the effective treatment of animal foot diseases The success of local drug applications is higher than systemic drug use. Farm Harmful to public health in milk and meat in the use of systemic drugs in animals there is a risk of residue. Antibacterial drugs administered regionally intravenously Difficulty in application compared to powder solutions or pomades to be used locally and the need for experience limits its practicality.
Sahada sigirlarin ayak hastaliklarinin tedavisinde lokal olarak kullanilan medikaller siklikla beseri antibakteriyel deri pomatlari, mastitis tedavisinde kullanilan meme içi preparatlar, antiseptik etkili çesitli toz ve solüsyonlardan olusmaktadir. Enfeksiyöz ayak hastaliklarinin tedavisinde kullanilan antiseptik etkili ilaçlar problemin çözümünde yetersiz kalmakta ve siklikla nükslerle sonuçlanmaktadir. Degisik antibakteriyel deri pomatlari ve meme içi kullanilan preparatlar ile sagaltima alinan yanitlarda standart degildir. Medicines used locally in the treatment of foot diseases of cattle in the field are often human antibacterial skin pomades, intramammary preparations used in the treatment of mastitis, It consists of various powders and solutions with antiseptic effect. Infectious foot diseases The antiseptic drugs used in the treatment are insufficient to solve the problem and often results in relapses. Various antibacterial skin pomades and intramammary pomades The preparations used and the responses to the treatment are not standard.
Konu ile ilgili, mevcut teknikte literatür taramasi yapildiginda rastlanilan basvurulardan biri TR2008/00666 basvuru numarali, 'Sigir ve domuzlarda enfeksiyonlari tedavi etmek için bilesimler ve usul, baslikli ulusal patent basvurusudur. Söz konusu basvuruda bulus, sigir ve domuzlarda görülen bulasici hastaliklarin tedavisinde ve önlenmesinde kullanimi için Fluniksin gibi bir steroid olmayan enflamasyon önleyici ilaç ile florfenikol gibi bir florlanmis kloroamfenikol veya tiamfenikol türevi antibiyotigi biraraya getiren yeni formülasyonlari içermektedir. One of the references found when a literature review is made on the subject in the current technique. Application number TR2008/00666, 'For the treatment of infections in cattle and pigs compositions and method is a national patent application entitled. In the application in question, invention, sigir and for use in the treatment and prevention of infectious diseases in pigs. A non-steroidal anti-inflammatory drug such as flunixin and a fluorinated drug such as florfenicol New formulations combining chloroamphenicol or thiamphenicol derivative antibiotic contains.
Diger bir basvuru ise CN “Büyükbas ayak hastaliginin tedavisi için kombine ilaç ve hazirlama yöntemi› baslikli Çin patent basvurusunda bulus, toz formunda olup, etilendiamin dihidroiyodür ve bakir sülfatin 1:2-223'Iük bir kütle oraninda karistirilmasiyla olusan kombine ilaci içerir. Etilendiamin dihidroiyodür ve bakir sülfatin reaksiyona girmesiyle ortaya çikan serbest elementel iyot patojenlerin hücre zari yapisini bozarak enfeksiyonu önleyebilir. Another application is CN “Combination for the treatment of cattle foot disease. The invention in the Chinese patent application titled “medicine and preparation method” is in powder form, by mixing ethylenediamine dihydroiodide and copper sulfate in a mass ratio of 1:2-223. Contains the combined drug. By reacting ethylenediamine dihydroiodide and copper sulfate The resulting free elemental iodine disrupts the cell membrane structure of pathogens and causes infection. can prevent.
Konu ile ilgili patentler incelendiginde çiftlik hayvanlarinda enfeksiyöz ayak hastaliklarinin tedavisinde kullanilmaya yönelik olarak lezyon alaninda tutunabilecek, emilebilen, lokal etkisi yüksek, ette ve sütte kalinti olusturmayacak, kolay uygulanabilir bir farmasötik kompozisyona olan gereksinim varligi ortaya çikmaktadir. When the patents on the subject are examined, it is seen that infectious foot diseases in farm animals Absorbable, local effect that can be adhered to the lesion area for use in the treatment of It has a high, easy to apply pharmaceutical composition that will not form residues in meat and milk. the existence of need emerges.
Sonuç olarak yukarida anlatilan olumsuzluklardan dolayi ve mevcut çözümlerin konu hakkindaki yetersizligi nedeniyle ilgili teknik alanda bir gelistirme yapilmasi gerekli kilinmistir. As a result, due to the above-mentioned negativities and existing solutions Due to the inadequacy of the subject, it was necessary to make an improvement in the related technical field.
Bulusun Kisa Açiklamasi Mevcut bulus, hayvanlarin enfeksiyöz ayak hastaliklarin tedavisine yönelik farmasötik kompozisyon ile ilgilidir. Brief Description of the Invention The present invention is a pharmaceutical for the treatment of infectious foot diseases of animals. It's about composition.
Bulusun baslica amaci, çiftlik hayvanlarinin enfeksiyöz ayak hastaliklari basta olmak 'üzere, hayvanlarda görülen her tür dekübital yaralar, ülseratif yaralar, kompresyon yaralari ve deri enfeksiyonlarinin lokal tedavisine yönelik bir farmasötik kompozisyon saglamaktir. The main aim of the invention is to 'infectious foot diseases of farm animals, in particular, all kinds of decubital wounds, ulcerative wounds, compression wounds and skin to provide a pharmaceutical composition for the local treatment of infections.
Bulusun benzer bir amaci, çiftlik hayvanlarinin enfeksiyöz ayak hastaliklarinda lezyon alaninda tutunabilecek, emilebilen, lokal etkisi yuksek, çiftlik hayvanlarinda ette ve sütte kalinti olusturmayacak, kolay uygulanabilir bir farmasötik kompozisyon saglamaktir. A similar object of the invention is the lesion in infectious foot diseases of farm animals. It can hold in the field, absorbable, has a high local effect, can be used in farm animals, meat and milk. It is to provide an easily applicable pharmaceutical composition that will not form residue.
Bulusun baska bir amaci, sigir, koyun, keçi gibi çiftlik hayvanlarinda enfeksiyöz ayak hastaliklarinin tedavisini saglayarak süt, et ve döl verimlerini arttirmaktir. Another object of the invention is to treat infectious foot disease in farm animals such as cattle, sheep, goats. It is to increase milk, meat and reproductive efficiency by providing the treatment of diseases.
Bulusun diger bir amaci, lokal uygulamada yüksek tedavi etkinligi saglamasi sayesinde, hayvanlardaki enfeksiyöz ayak hastaliklarinda tedavi amaçli birim ilaç maliyetini düsürülmesinin saglanmasidir. Another object of the invention is that it provides high therapeutic efficacy in local application, unit cost of drug for treatment in infectious foot diseases in animals. is to ensure its lowering.
Bulus, yukarida anlatilan amaçlarin yerine getirilmesi için, çiftlik hayvanlarinin enfeksiyöz ayak hastaliklari basta olmak üzere, hayvanlarda görülen her tür dekübital yaralar, ülseratif yaralar, kompresyon yaralari ve deri enfeksiyonlarinin lokal tedavisine yönelik, antibiyotik özellikli etken madde olarak azitromisin veya farmasötik olarak kabul edilebilir bir türevi ve farmasötik olarak uygun en az bir yardimci madde içeren farmasötik kompozisyon olup; özelligi; antiseptik özellikli etken madde olarak borik asit, çinko oksit, fenol, klorobutanol; antioksidan özellikli etken madde olarak N- asetil sistein, alfa tokaferol, askorbik asit içermesidir. In order to fulfill the above-described purposes, the invention is intended to treat infectious diseases of farm animals. all kinds of decubital wounds in animals, ulcerative antibiotic for the local treatment of wounds, compression wounds and skin infections azithromycin or a pharmaceutically acceptable derivative as the specific active ingredient, and pharmaceutical composition comprising at least one pharmaceutically acceptable excipient; feature; boric acid, zinc oxide, phenol, chlorobutanol as an antiseptic active ingredient; N-acetyl cysteine, alpha tocapherol, ascorbic acid as active ingredient with antioxidant properties it contains.
Bulusun yapisal ve karakteristik özellikleri ve tüm avantajlari, asagida verilen sekiller ve bu sekillere atiflar yapilmak suretiyle yazilan detayli açiklama sayesinde daha net olarak anlasilacaktir. Bu nedenle degerlendirmenin de bu sekiller ve detayli açiklama göz önüne alinarak yapilmasi gerekmektedir. Structural and characteristic features of the invention and all its advantages, the following figures and this More clearly thanks to the detailed explanation with references to the figures. will be understood. For this reason, the evaluation should take these figures and detailed explanation into consideration. must be made by taking
Sonuç olarak yukarida anlatilan olumsuzluklardan dolayi ve mevcut çözümlerin konu hakkindaki yetersizligi nedeniyle ilgili teknik alanda bir gelistirme yapilmasi gerekli kilinmistir. As a result, due to the above-mentioned negativities and existing solutions Due to the inadequacy of the subject, it was necessary to make an improvement in the related technical field.
Bulusun Kisa Açiklamasi Mevcut bulus, hayvanlarin enfeksiyöz ayak hastaliklarin tedavisine yönelik farmasötik kompozisyon ile ilgilidir. Brief Description of the Invention The present invention is a pharmaceutical for the treatment of infectious foot diseases of animals. It's about composition.
Bulusun baslica amaci, çiftlik hayvanlarinin enfeksiyöz ayak hastaliklari basta olmak 'üzere, hayvanlarda görülen her tür dekübital yaralar, ülseratif yaralar, kompresyon yaralari ve deri enfeksiyonlarinin lokal tedavisine yönelik bir farmasötik kompozisyon saglamaktir. The main aim of the invention is to 'infectious foot diseases of farm animals, in particular, all kinds of decubital wounds, ulcerative wounds, compression wounds and skin to provide a pharmaceutical composition for the local treatment of infections.
Bulusun benzer bir amaci, çiftlik hayvanlarinin enfeksiyöz ayak hastaliklarinda lezyon alaninda tutunabilecek, emilebilen, lokal etkisi yuksek, çiftlik hayvanlarinda ette ve sütte kalinti olusturmayacak, kolay uygulanabilir bir farmasötik kompozisyon saglamaktir. A similar object of the invention is the lesion in infectious foot diseases of farm animals. It can hold in the field, absorbable, has a high local effect, can be used in farm animals, meat and milk. It is to provide an easily applicable pharmaceutical composition that will not form residue.
Bulusun baska bir amaci, sigir, koyun, keçi gibi çiftlik hayvanlarinda enfeksiyöz ayak hastaliklarinin tedavisini saglayarak süt, et ve döl verimlerini arttirmaktir. Another object of the invention is to treat infectious foot disease in farm animals such as cattle, sheep, goats. It is to increase milk, meat and reproductive efficiency by providing the treatment of diseases.
Bulusun diger bir amaci, lokal uygulamada yüksek tedavi etkinligi saglamasi sayesinde, hayvanlardaki enfeksiyöz ayak hastaliklarinda tedavi amaçli birim ilaç maliyetini düsürülmesinin saglanmasidir. Another object of the invention is that it provides high therapeutic efficacy in local application, unit cost of drug for treatment in infectious foot diseases in animals. is to ensure its lowering.
Bulus, yukarida anlatilan amaçlarin yerine getirilmesi için, çiftlik hayvanlarinin enfeksiyöz ayak hastaliklari basta olmak üzere, hayvanlarda görülen her tür dekübital yaralar, ülseratif yaralar, kompresyon yaralari ve deri enfeksiyonlarinin lokal tedavisine yönelik, antibiyotik özellikli etken madde olarak azitromisin veya farmasötik olarak kabul edilebilir bir türevi ve farmasötik olarak uygun en az bir yardimci madde içeren farmasötik kompozisyon olup; özelligi; antiseptik özellikli etken madde olarak borik asit, çinko oksit, fenol, klorobutanol; antioksidan özellikli etken madde olarak N- asetil sistein, alfa tokaferol, askorbik asit içermesidir. In order to fulfill the above-described purposes, the invention is intended to treat infectious diseases of farm animals. all kinds of decubital wounds in animals, ulcerative antibiotic for the local treatment of wounds, compression wounds and skin infections azithromycin or a pharmaceutically acceptable derivative as the specific active ingredient, and pharmaceutical composition comprising at least one pharmaceutically acceptable excipient; feature; boric acid, zinc oxide, phenol, chlorobutanol as an antiseptic active ingredient; N-acetyl cysteine, alpha tocapherol, ascorbic acid as active ingredient with antioxidant properties it contains.
Bulusun yapisal ve karakteristik özellikleri ve tüm avantajlari, asagida verilen sekiller ve bu sekillere atiflar yapilmak suretiyle yazilan detayli açiklama sayesinde daha net olarak anlasilacaktir. Bu nedenle degerlendirmenin de bu sekiller ve detayli açiklama göz önüne alinarak yapilmasi gerekmektedir. Structural and characteristic features of the invention and all its advantages, the following figures and this More clearly thanks to the detailed explanation with references to the figures. will be understood. For this reason, the evaluation should take these figures and detailed explanation into consideration. must be made by taking
Bulusun Anlasilmasina Yardimci Olacak Sekiller Sekil 1, Bulus konusu farmasotik kompozisyonun akut agrili dermatitis lezyonu `uzerinde uygulama görüntüleridir. Figures to Help Understand the Invention Figure 1, On the acute painful dermatitis lesion of the pharmaceutical composition of the invention application images.
Sekil 2A, digital dermatitisli olguda sagaltim öncesi görüntüleridir. Figure 2A is the pre-treatment images of the patient with digital dermatitis.
Sekil 28, digital dermatitisli olguda sagaltim sonrasi 6. günde ilk pansuman sonrasi tam sifa görüntüleridir. Figure 28, full healing after the first dressing on the 6th day after treatment in a case with digital dermatitis are images.
Sekil 3A, bilateral ökçe ve digital dermatitis Iezyonlarinda sagaltim oncesi görüntüleridir. Figure 3A is the pre-treatment images of bilateral heel and digital dermatitis lesions.
Sekil SB, bilateral 'Ökçe ve digital dermatitis Iezyonlarinda sagaltim sonrasi 6. günde ilk pansuman sonrasi tam sifa görüntüsüdür. Figure SB, bilateral 'Heel and digital dermatitis lesions on the 6th day after the first treatment It is a full healing image after dressing.
Sekil 4A, uniteral digital dermatitis ve interdigital aralik baslangicindaki dermatitis Sekil 48, uniteral digital dermatitis ve interdigital aralik baslangicindaki dermatitis Sekil 5A. interdigital dermatitis olgusunda sagaltim öncesi görüntüsüdür. Figure 4A, unitary digital dermatitis and dermatitis at the onset of the interdigital interval Figure 48, unitary digital dermatitis and dermatitis at the onset of the interdigital interval Figure 5A. is the preoperative view in a case of interdigital dermatitis.
Sekil SB. interdigital dermatitis olgusunda sagaltim sonrasi 7. Gündeki ilk pansuman kontrolünde tam sifa görüntüsüdür. Figure SB. The first dressing on the 7th day after treatment in a case of interdigital dermatitis It is a full healing image under control.
Bulusun anlasilirligini saglamak için sekiller renkli görüntü olarak sunulmaktadir. Figures are presented as color images for clarity of the invention.
Bulusun Detayli Açiklamasi Bu detayli açiklamada, bulus konusu farmasbtik kompozisyon ve tercih edilen formülasyonlari, sadece konunun daha iyi anlasilmasina yönelik olarak ve hiçbir sinirlayici etki olusturmayacak sekilde açiklanmaktadir. Detailed Description of the Invention In this detailed description, the pharmaceutical composition of the invention and the preferred formulations are intended only for a better understanding of the subject and without limiting are explained in a way that has no effect.
Bulus, ozellikle sigir, koyun , keçi gibi çiftlik hayvanlarinda enfeksiyöz ayak hastaliklari basta olmak üzere, hayvanlarda görülen her tür dek'übital yaralar, ülseratif yaralar, kompresyon yaralari ve deri enfeksiyonlarinin lokal tedavisine yönelik bir farmas'otik kompozisyon olup ; Bulusun Anlasilmasina Yardimci Olacak Sekiller Sekil 1, Bulus konusu farmasotik kompozisyonun akut agrili dermatitis lezyonu `uzerinde uygulama görüntüleridir. Infectious foot diseases especially in farm animals such as cattle, sheep and goats. all kinds of animal decubital wounds, ulcerative wounds, compression It is a pharmaceutical composition for the local treatment of wounds and skin infections; Figures to Help Understand the Invention Figure 1, On the acute painful dermatitis lesion of the pharmaceutical composition of the invention application images.
Sekil 2A, digital dermatitisli olguda sagaltim öncesi görüntüleridir. Figure 2A is the pre-treatment images of the patient with digital dermatitis.
Sekil 28, digital dermatitisli olguda sagaltim sonrasi 6. günde ilk pansuman sonrasi tam sifa görüntüleridir. Figure 28, full healing after the first dressing on the 6th day after treatment in a case with digital dermatitis are images.
Sekil 3A, bilateral ökçe ve digital dermatitis Iezyonlarinda sagaltim oncesi görüntüleridir. Figure 3A is the pre-treatment images of bilateral heel and digital dermatitis lesions.
Sekil SB, bilateral 'Ökçe ve digital dermatitis Iezyonlarinda sagaltim sonrasi 6. günde ilk pansuman sonrasi tam sifa görüntüsüdür. Figure SB, bilateral 'Heel and digital dermatitis lesions on the 6th day after the first treatment It is a full healing image after dressing.
Sekil 4A, uniteral digital dermatitis ve interdigital aralik baslangicindaki dermatitis Sekil 48, uniteral digital dermatitis ve interdigital aralik baslangicindaki dermatitis Sekil 5A. interdigital dermatitis olgusunda sagaltim öncesi görüntüsüdür. Figure 4A, unitary digital dermatitis and dermatitis at the onset of the interdigital interval Figure 48, unitary digital dermatitis and dermatitis at the onset of the interdigital interval Figure 5A. is the preoperative view in a case of interdigital dermatitis.
Sekil SB. interdigital dermatitis olgusunda sagaltim sonrasi 7. Gündeki ilk pansuman kontrolünde tam sifa görüntüsüdür. Figure SB. The first dressing on the 7th day after treatment in a case of interdigital dermatitis It is a full healing image under control.
Bulusun anlasilirligini saglamak için sekiller renkli görüntü olarak sunulmaktadir. Figures are presented as color images for clarity of the invention.
Bulusun Detayli Açiklamasi Bu detayli açiklamada, bulus konusu farmasbtik kompozisyon ve tercih edilen formülasyonlari, sadece konunun daha iyi anlasilmasina yönelik olarak ve hiçbir sinirlayici etki olusturmayacak sekilde açiklanmaktadir. Detailed Description of the Invention In this detailed description, the pharmaceutical composition of the invention and the preferred formulations are intended only for a better understanding of the subject and without limiting are explained in a way that has no effect.
Bulus, ozellikle sigir, koyun , keçi gibi çiftlik hayvanlarinda enfeksiyöz ayak hastaliklari basta olmak üzere, hayvanlarda görülen her tür dek'übital yaralar, ülseratif yaralar, kompresyon yaralari ve deri enfeksiyonlarinin lokal tedavisine yönelik bir farmas'otik kompozisyon olup ; antibiyotik `özellikli etken maddenin, antiseptik Özellikli ve antioksidan özellikli etken maddelerle kombine edilmesi esasina dayanmaktadir. Infectious foot diseases especially in farm animals such as cattle, sheep and goats. all kinds of animal decubital wounds, ulcerative wounds, compression It is a pharmaceutical composition for the local treatment of wounds and skin infections; the active substance with antibiotic properties, the agent with antiseptic and antioxidant properties based on the combination of substances.
Bulus, hayvanlarin enfeksiyöz ayak hastaliklarinda olusan Iezyonlarda bulunan patojen mikroorganizmalari öldürmek amaciyla makrolid grubu antibiyotik etken madde olarak azitromisin veya farmasötik olarak kabul edilebilir türevlerini içermektedir. Invention, pathogen found in lesions of infectious foot diseases of animals As a macrolide group antibiotic active ingredient to kill microorganisms Azithromycin or its pharmaceutically acceptable derivatives.
Burada “farmasötik olarak kabul edilebilir türevleri" terimi farmasötik olarak kabul edilebilir uygun tuzlari, esterleri, solvatlari, hidratlari, kompleksleri, izomerleri, konjugeleri gibi türevleri ifade etmektedir. The term "pharmaceutically acceptable derivatives" herein is pharmaceutically acceptable. derivatives such as suitable salts, esters, solvates, hydrates, complexes, isomers, conjugates means.
Burada “antiseptik” terimi enfeksiyon, septisemi veya çürümeyi önlemek amaciyla canli dokuya uygulanan mikrop karsiti (antimikrobiyal) maddeleri ifade etmektedir. Bulus antiseptik Burada “antioksidan” terimi serbest radikallerin neden olduklari oksidasyonlari önleyen maddeleri ifade etmektedir. Bulus , antioksidan özellikli etken madde olarak N asetil sistein, alfa tokaferol (E vitamini) ve askorbik asit (C vitamini) içermektedir. Söz konusu antioksidan maddeler bulus konusu farmasbtik kompozisyonun stabilitesini saglarken yara dokusunun iyilesmesine de yardimci olmaktadirlar. The term "antiseptic" is used here to prevent infection, septicemia, or rot. refers to antimicrobial (antimicrobial) substances applied to the tissue. Invention antiseptic The term "antioxidant" is used here to prevent oxidation caused by free radicals. means items. Invention, N acetyl cysteine as active ingredient with antioxidant properties, It contains alpha tocapherol (vitamin E) and ascorbic acid (vitamin C). The antioxidant While the substances provide the stability of the pharmaceutical composition of the invention, the scar tissue They also help with recovery.
Mevcut bulus yukarida belirtilen etken maddelerlerin yaninda tercihen, yara dokusunun iyilesmesine ve saglikli tirnak dokusu üretimine yardimci olan mineraller de içerebilir. Mineral olarak bakir, demir, flor, iyot, krom, magnezyum, mangan, molibden, selenyum, potasyum, kalsiyum, borat, alüminyum, klor, zirkonyum veya bu minerallerin farmas'otik olarak kabul edilebilir uygun türevlerini içeren gruptan seçilmis birey veya kombinasyonlar kullanilabilir. The present invention, besides the above-mentioned active ingredients, preferably produces scar tissue It may also contain minerals that aid in healing and the production of healthy nail tissue. Mineral as copper, iron, fluorine, iodine, chromium, magnesium, manganese, molybdenum, selenium, potassium, calcium, borate, aluminum, chlorine, zirconium or these minerals are not considered pharmaceuticals. Individuals or combinations selected from the group consisting of suitable derivatives may be used.
Mevcut bulusun tercih edilen bir yapilanmasi bakir, demir, flor, iyot, krom, magnezyum, mangan, molibden, selenyum veya bu minerallerin farmas'otik olarak kabul edilebilir uygun türevlerini içermektedir. A preferred embodiment of the present invention is copper, iron, fluorine, iodine, chromium, magnesium, manganese, molybdenum, selenium or pharmaceutically acceptable suitable includes derivatives.
Mevcut bulus, lokal (topikal) uygulanabilecek bir farmasötik kompozisyon saglamak için, içerdigi etken maddelerin yaninda en az bir yardimci madde de Içermektedir. Bahsedilen yardimci madde, en az bir tasiyici ajan, en az bir tamponlayici ajan, en az bir kivam artirici ajan içeren gruptan seçilmis birey veya kombinasyonlardir. The present invention provides a pharmaceutical composition that can be applied topically. In addition to the active ingredients it contains, it also contains at least one auxiliary substance. Said excipient, at least one carrier agent, at least one buffering agent, at least one thickener are individuals or combinations selected from the group containing the agent.
Burada “tasiyici ajan” (sivag) etken maddelerin uygulama alanina daha iyi nüfuz edebilmesi veya iyi doze edilebilmesi için katilan fizyolojik etkisi olmayan yardimci maddeleri ifade eder. antibiyotik `özellikli etken maddenin, antiseptik Özellikli ve antioksidan özellikli etken maddelerle kombine edilmesi esasina dayanmaktadir. Here, the "carrier agent" (sivag) allows the active ingredients to penetrate better into the application area. or additives that do not have a physiological effect in order to be well dosed. the active substance with antibiotic properties, the agent with antiseptic and antioxidant properties based on the combination of substances.
Bulus, hayvanlarin enfeksiyöz ayak hastaliklarinda olusan Iezyonlarda bulunan patojen mikroorganizmalari öldürmek amaciyla makrolid grubu antibiyotik etken madde olarak azitromisin veya farmasötik olarak kabul edilebilir türevlerini içermektedir. Invention, pathogen found in lesions of infectious foot diseases of animals As a macrolide group antibiotic active ingredient to kill microorganisms Azithromycin or its pharmaceutically acceptable derivatives.
Burada “farmasötik olarak kabul edilebilir türevleri" terimi farmasötik olarak kabul edilebilir uygun tuzlari, esterleri, solvatlari, hidratlari, kompleksleri, izomerleri, konjugeleri gibi türevleri ifade etmektedir. The term "pharmaceutically acceptable derivatives" herein is pharmaceutically acceptable. derivatives such as suitable salts, esters, solvates, hydrates, complexes, isomers, conjugates means.
Burada “antiseptik” terimi enfeksiyon, septisemi veya çürümeyi önlemek amaciyla canli dokuya uygulanan mikrop karsiti (antimikrobiyal) maddeleri ifade etmektedir. Bulus antiseptik Burada “antioksidan” terimi serbest radikallerin neden olduklari oksidasyonlari önleyen maddeleri ifade etmektedir. Bulus , antioksidan özellikli etken madde olarak N asetil sistein, alfa tokaferol (E vitamini) ve askorbik asit (C vitamini) içermektedir. Söz konusu antioksidan maddeler bulus konusu farmasbtik kompozisyonun stabilitesini saglarken yara dokusunun iyilesmesine de yardimci olmaktadirlar. The term "antiseptic" is used here to prevent infection, septicemia, or rot. refers to antimicrobial (antimicrobial) substances applied to the tissue. Invention antiseptic The term "antioxidant" is used here to prevent oxidation caused by free radicals. means items. Invention, N acetyl cysteine as active ingredient with antioxidant properties, It contains alpha tocapherol (vitamin E) and ascorbic acid (vitamin C). The antioxidant While the substances provide the stability of the pharmaceutical composition of the invention, the scar tissue They also help with recovery.
Mevcut bulus yukarida belirtilen etken maddelerlerin yaninda tercihen, yara dokusunun iyilesmesine ve saglikli tirnak dokusu üretimine yardimci olan mineraller de içerebilir. Mineral olarak bakir, demir, flor, iyot, krom, magnezyum, mangan, molibden, selenyum, potasyum, kalsiyum, borat, alüminyum, klor, zirkonyum veya bu minerallerin farmas'otik olarak kabul edilebilir uygun türevlerini içeren gruptan seçilmis birey veya kombinasyonlar kullanilabilir. The present invention, besides the above-mentioned active ingredients, preferably produces scar tissue It may also contain minerals that aid in healing and the production of healthy nail tissue. Mineral as copper, iron, fluorine, iodine, chromium, magnesium, manganese, molybdenum, selenium, potassium, calcium, borate, aluminum, chlorine, zirconium or these minerals are not considered pharmaceuticals. Individuals or combinations selected from the group consisting of suitable derivatives may be used.
Mevcut bulusun tercih edilen bir yapilanmasi bakir, demir, flor, iyot, krom, magnezyum, mangan, molibden, selenyum veya bu minerallerin farmas'otik olarak kabul edilebilir uygun türevlerini içermektedir. A preferred embodiment of the present invention is copper, iron, fluorine, iodine, chromium, magnesium, manganese, molybdenum, selenium or pharmaceutically acceptable suitable includes derivatives.
Mevcut bulus, lokal (topikal) uygulanabilecek bir farmasötik kompozisyon saglamak için, içerdigi etken maddelerin yaninda en az bir yardimci madde de Içermektedir. Bahsedilen yardimci madde, en az bir tasiyici ajan, en az bir tamponlayici ajan, en az bir kivam artirici ajan içeren gruptan seçilmis birey veya kombinasyonlardir. The present invention provides a pharmaceutical composition that can be applied topically. In addition to the active ingredients it contains, it also contains at least one auxiliary substance. Said excipient, at least one carrier agent, at least one buffering agent, at least one thickener are individuals or combinations selected from the group containing the agent.
Burada “tasiyici ajan” (sivag) etken maddelerin uygulama alanina daha iyi nüfuz edebilmesi veya iyi doze edilebilmesi için katilan fizyolojik etkisi olmayan yardimci maddeleri ifade eder. Here, the "carrier agent" (sivag) allows the active ingredients to penetrate better into the application area. or additives that do not have a physiological effect in order to be well dosed.
Tasiyici ajan olarak susuz Ianolin, vazelin, domuz yagi içeren gruptan seçilmis birey veya kombinasyonlar kullanilabilir. Mevcut bulusun tercih edilen bir yapilanmasi susuz Ianolin ve vazelin içermektedir. An individual selected from the group containing anhydrous Ianolin, petrolatum, lard as the carrier agent, or combinations can be used. A preferred embodiment of the present invention is anhydrous Ianolin and Contains vaseline.
Burada “tamponlayici ajan” terimi, bulus konusu farmasötik kompozisyonun asitlik ve bazlik özelligini düzenleyen maddeleri ifade etmektedir. Tamponlayici ajan (pH düzenleyici ) olarak; sodyum bikarbonat, amonyak, sodyum hidroksit, sodyum sitrat, histidin içeren gruptan seçilmis birey veya kombinasyonlar kullanilabilir. Mevcut bulusun tercih edilen bir yapilanmasi sodyum bikarbonat içermektedir. The term "buffering agent" herein refers to the acidity and basicity of the pharmaceutical composition of the invention. refers to the substances that regulate its property. As a buffering agent (pH regulator); from the group containing sodium bicarbonate, ammonia, sodium hydroxide, sodium citrate, histidine selected individuals or combinations may be used. The present invention is a preferred The formulation contains sodium bicarbonate.
Burada “kivam arttirici ajan” terimi bulus konusu farmasötik kompozisyonun viskozitesini artirarak, kompozisyonun bütünlügünü dis etkenlere karsi güçlendiren maddeleri ifade etmektedir. Kivam arttirici ajan olarak setil alkol, aljinik asit, sodyum aljinat, potasyum aljinat, amonyum aljinat, kalsiyum aljinat, pektin, jelatin, beyaz balmumu içeren gruptan seçilmis birey veya kombinasyonlar kullanilabilir. Mevcut bulusun tercih edilen bir yapilanmasi setil alkol içermektedir. Here, the term "thickening agent" refers to the viscosity of the pharmaceutical composition of the invention. Expressing substances that strengthen the integrity of the composition against external factors by increasing is doing. Cetyl alcohol, alginic acid, sodium alginate, potassium alginate as a thickening agent, selected from the group consisting of ammonium alginate, calcium alginate, pectin, gelatin, white beeswax Individuals or combinations may be used. A preferred embodiment of the present invention is set Contains alcohol.
Bulus konusu farmasötik kompozisyon lokal (topikal) uygulama için bunlarla kisitli olmamakla beraber pomat, krem, jel, merhem, losyon, süspansiyon, emülsiyon, macun, köpük, solüsyon veya sprey gibi farkli dozaj formunda olabilir. Mevcut bulusun tercih edilen yapilanmasi pomat formundadir. The pharmaceutical composition of the invention is not limited thereto for local (topical) administration. together with ointment, cream, gel, ointment, lotion, suspension, emulsion, paste, foam, solution or in a different dosage form, such as a spray. Preferred embodiment of the present invention in pomade form.
On çalismalar: Bulus kapsaminda yapilan ön çalismalarda, asagida verilen Tablo 1te uygun olarak hazirlanan bulusun tercih edilen yapilanmalari, sigirlarda görülen ayak hastaliklarinda seçilen 'örnek olgularda tedavi için kullanilmis ve alinan olumlu sonuçlar görüntülenmistir. Ten studies: In the preliminary studies carried out within the scope of the invention, in accordance with Table 1 given below The preferred embodiments of the present invention are used in foot diseases in cattle. It was used for treatment in selected 'example cases' and positive results were observed.
Tablo 1. Bulusun tercih edilen yapilanmasinin içerdigi hammaddeler Hammadde Agirlikça Kullanilabilir Miktar % Azitromisin 1 -5 Borik asit 1-5 Çinko oksit 2-20 Klorobutanol 0,2-1 N Asetil Sistein 0,2-1 Tasiyici ajan olarak susuz Ianolin, vazelin, domuz yagi içeren gruptan seçilmis birey veya kombinasyonlar kullanilabilir. Mevcut bulusun tercih edilen bir yapilanmasi susuz Ianolin ve vazelin içermektedir. Table 1. Raw materials of the preferred embodiment of the invention Usable Amount by Weight of Raw Material % Azithromycin 1 -5 Boric acid 1-5 Zinc oxide 2-20 Chlorobutanol 0.2-1 N Acetyl Cysteine 0.2-1 An individual selected from the group containing anhydrous Ianolin, petrolatum, lard as the carrier agent, or combinations can be used. A preferred embodiment of the present invention is anhydrous Ianolin and Contains vaseline.
Burada “tamponlayici ajan” terimi, bulus konusu farmasötik kompozisyonun asitlik ve bazlik özelligini düzenleyen maddeleri ifade etmektedir. Tamponlayici ajan (pH düzenleyici ) olarak; sodyum bikarbonat, amonyak, sodyum hidroksit, sodyum sitrat, histidin içeren gruptan seçilmis birey veya kombinasyonlar kullanilabilir. Mevcut bulusun tercih edilen bir yapilanmasi sodyum bikarbonat içermektedir. The term "buffering agent" herein refers to the acidity and basicity of the pharmaceutical composition of the invention. refers to the substances that regulate its property. As a buffering agent (pH regulator); from the group containing sodium bicarbonate, ammonia, sodium hydroxide, sodium citrate, histidine selected individuals or combinations may be used. The present invention is a preferred The formulation contains sodium bicarbonate.
Burada “kivam arttirici ajan” terimi bulus konusu farmasötik kompozisyonun viskozitesini artirarak, kompozisyonun bütünlügünü dis etkenlere karsi güçlendiren maddeleri ifade etmektedir. Kivam arttirici ajan olarak setil alkol, aljinik asit, sodyum aljinat, potasyum aljinat, amonyum aljinat, kalsiyum aljinat, pektin, jelatin, beyaz balmumu içeren gruptan seçilmis birey veya kombinasyonlar kullanilabilir. Mevcut bulusun tercih edilen bir yapilanmasi setil alkol içermektedir. Here, the term "thickening agent" refers to the viscosity of the pharmaceutical composition of the invention. Expressing substances that strengthen the integrity of the composition against external factors by increasing is doing. Cetyl alcohol, alginic acid, sodium alginate, potassium alginate as a thickening agent, selected from the group consisting of ammonium alginate, calcium alginate, pectin, gelatin, white beeswax Individuals or combinations may be used. A preferred embodiment of the present invention is set Contains alcohol.
Bulus konusu farmasötik kompozisyon lokal (topikal) uygulama için bunlarla kisitli olmamakla beraber pomat, krem, jel, merhem, losyon, süspansiyon, emülsiyon, macun, köpük, solüsyon veya sprey gibi farkli dozaj formunda olabilir. Mevcut bulusun tercih edilen yapilanmasi pomat formundadir. The pharmaceutical composition of the invention is not limited thereto for local (topical) administration. together with ointment, cream, gel, ointment, lotion, suspension, emulsion, paste, foam, solution or in a different dosage form, such as a spray. Preferred embodiment of the present invention in pomade form.
On çalismalar: Bulus kapsaminda yapilan ön çalismalarda, asagida verilen Tablo 1te uygun olarak hazirlanan bulusun tercih edilen yapilanmalari, sigirlarda görülen ayak hastaliklarinda seçilen 'örnek olgularda tedavi için kullanilmis ve alinan olumlu sonuçlar görüntülenmistir. Ten studies: In the preliminary studies carried out within the scope of the invention, in accordance with Table 1 given below The preferred embodiments of the present invention are used in foot diseases in cattle. It was used for treatment in selected 'example cases' and positive results were observed.
Tablo 1. Bulusun tercih edilen yapilanmasinin içerdigi hammaddeler Hammadde Agirlikça Kullanilabilir Miktar % Azitromisin 1 -5 Borik asit 1-5 Çinko oksit 2-20 Klorobutanol 0,2-1 N Asetil Sistein 0,2-1 Alfa tokaferol 0,5-2 Askorbik asit 0,5-2 Magnezyum 0,5-2,5 Molibden 0,0001-0,001 Selenyum 0,0001-0,001 Setil alkol 1_5 Sodyum Bikarbonat 0,5-5 Susuz Lanolin 10-30 Vazelin 10-60 Bulusun tercih edilen bir yapilanmasi, Tablo 1'de verilen miktarlara uygun olarak hazirlanan hammaddeler ile pomat formunda hazirlanmistir. Tasiyici (sivag) ajan olan Ianolin ve vazelin ile kivam arttirici ajan olan setil alkol 60 °C sicaklikta eritilerek karistirilir. Homojen bir sivag karisimi saglaninca karistirilarak sogutulmaya baslanir. Ayri bir yerde formülasyonda bulunan kati fazda olan hammaddeler (azitromisin, borik asit, çinko oksit, askorbik asit, sodyum bikarbonat) oda sicakliginda (22 °C) karistirilir ve üzerine sivi fazdaki hammaddeler magnezyum, mangan, molibden, selenyum çözeltisi)] ilave edilerek karistirilir. Elde edilen karisim, sicakligi 35-38°Ciye düsürülen sivag karisimina asilanir ve karistirilarak sogutmaya devam edilir. Karisimin sicakligi 25 °C'ye geldiginde antioksidan madde alfa tokaferol ilave edilerek karistirilir ve pomat formu elde edilir. Table 1. Raw materials of the preferred embodiment of the invention Usable Amount by Weight of Raw Material % Azithromycin 1 -5 Boric acid 1-5 Zinc oxide 2-20 Chlorobutanol 0.2-1 N Acetyl Cysteine 0.2-1 Alpha tocapherol 0.5-2 Ascorbic acid 0.5-2 Magnesium 0.5-2.5 Molybdenum 0.0001-0.001 Selenium 0.0001-0.001 Cetyl alcohol 1_5 Sodium Bicarbonate 0.5-5 Anhydrous Lanolin 10-30 Vaseline 10-60 A preferred embodiment of the invention is prepared in accordance with the amounts given in Table 1. It is prepared in pomade form with raw materials. Ianolin and petrolatum, which are carrier (sivag) agents and cetyl alcohol, which is a thickening agent, is melted at 60 °C and mixed. A homogeneous sivag When the mixture is provided, it is mixed and cooled. Formulation in a separate place solid phase raw materials (azithromycin, boric acid, zinc oxide, ascorbic acid, sodium bicarbonate) is mixed at room temperature (22 °C) and the raw materials in the liquid phase are added on. magnesium, manganese, molybdenum, selenium solution)] is added and mixed. Obtained the mixture is suspended in the plaster mixture, the temperature of which is lowered to 35-38°C, and mixed and cooled. continues. When the temperature of the mixture reaches 25 °C, the antioxidant substance alpha tocapherol is added. It is mixed and the pomade form is obtained.
Elde edilen pomadin orijinal ambalajinda ve kapali olarak , günes isigina direk maruz kalmayacak sekilde muhafaza edildiginde, oda sicakliginda 7 gün buzdolabinda 14 gün stabilizasyonunun korundugu öngörülmüstür. The obtained pomade should be stored in its original packaging and closed, under direct exposure to sunlight. 7 days at room temperature, 14 days in the refrigerator It is predicted that the stabilization is preserved.
Bulus konusu farmasötik kompozisyon kati, sivi ve sivag faz olmak üzere üç kompartmanli olarak sunulabilir. Bu durumda, her bir kopartmanin karistirilmadan önceki stabilizasyonunun 2 yil oldugu öngörülmektedir. The pharmaceutical composition of the invention consists of three compartments: solid, liquid and liquid phase. can be presented as In this case, the stabilization of each breakout before mixing It is estimated to be 2 years.
Bulusun pomat formundaki tercih edilen yapilanmasi, sigirlarin ayak hastaliklarinda olusan lezyon bölgesini örten 2-3 mm lik bir tabaka olusturacak sekilde sürülerek uygulanir. The preferred embodiment of the invention in the form of ointment is in the foot diseases of cattle. It is applied by applying to form a 2-3 mm layer covering the lesion area.
Uygulama öncesinde bölgenin mekanik temizliginin yapilmasi , lezyon üzerinin küretaji, Alfa tokaferol 0,5-2 Askorbik asit 0,5-2 Magnezyum 0,5-2,5 Molibden 0,0001-0,001 Selenyum 0,0001-0,001 Setil alkol 1_5 Sodyum Bikarbonat 0,5-5 Susuz Lanolin 10-30 Vazelin 10-60 Bulusun tercih edilen bir yapilanmasi, Tablo 1'de verilen miktarlara uygun olarak hazirlanan hammaddeler ile pomat formunda hazirlanmistir. Tasiyici (sivag) ajan olan Ianolin ve vazelin ile kivam arttirici ajan olan setil alkol 60 °C sicaklikta eritilerek karistirilir. Homojen bir sivag karisimi saglaninca karistirilarak sogutulmaya baslanir. Ayri bir yerde formülasyonda bulunan kati fazda olan hammaddeler (azitromisin, borik asit, çinko oksit, askorbik asit, sodyum bikarbonat) oda sicakliginda (22 °C) karistirilir ve üzerine sivi fazdaki hammaddeler magnezyum, mangan, molibden, selenyum çözeltisi)] ilave edilerek karistirilir. Elde edilen karisim, sicakligi 35-38°Ciye düsürülen sivag karisimina asilanir ve karistirilarak sogutmaya devam edilir. Karisimin sicakligi 25 °C'ye geldiginde antioksidan madde alfa tokaferol ilave edilerek karistirilir ve pomat formu elde edilir. Mechanical cleaning of the area before the application, curettage of the lesion, Alpha tocapherol 0.5-2 Ascorbic acid 0.5-2 Magnesium 0.5-2.5 Molybdenum 0.0001-0.001 Selenium 0.0001-0.001 Cetyl alcohol 1_5 Sodium Bicarbonate 0.5-5 Anhydrous Lanolin 10-30 Vaseline 10-60 A preferred embodiment of the invention is prepared in accordance with the amounts given in Table 1. It is prepared in pomade form with raw materials. Ianolin and petrolatum, which are carrier (sivag) agents and cetyl alcohol, which is a thickening agent, is melted at 60 °C and mixed. A homogeneous sivag When the mixture is provided, it is mixed and cooled. Formulation in a separate place solid phase raw materials (azithromycin, boric acid, zinc oxide, ascorbic acid, sodium bicarbonate) is mixed at room temperature (22 °C) and the raw materials in the liquid phase are added on. magnesium, manganese, molybdenum, selenium solution)] is added and mixed. Obtained the mixture is suspended in the plaster mixture, the temperature of which is lowered to 35-38°C, and mixed and cooled. continues. When the temperature of the mixture reaches 25 °C, the antioxidant substance alpha tocapherol is added. It is mixed and the pomade form is obtained.
Elde edilen pomadin orijinal ambalajinda ve kapali olarak , günes isigina direk maruz kalmayacak sekilde muhafaza edildiginde, oda sicakliginda 7 gün buzdolabinda 14 gün stabilizasyonunun korundugu öngörülmüstür. The obtained pomade should be stored in its original packaging and closed, under direct exposure to sunlight. 7 days at room temperature, 14 days in the refrigerator It is predicted that the stabilization is preserved.
Bulus konusu farmasötik kompozisyon kati, sivi ve sivag faz olmak üzere üç kompartmanli olarak sunulabilir. Bu durumda, her bir kopartmanin karistirilmadan önceki stabilizasyonunun 2 yil oldugu öngörülmektedir. The pharmaceutical composition of the invention consists of three compartments: solid, liquid and liquid phase. can be presented as In this case, the stabilization of each breakout before mixing It is estimated to be 2 years.
Bulusun pomat formundaki tercih edilen yapilanmasi, sigirlarin ayak hastaliklarinda olusan lezyon bölgesini örten 2-3 mm lik bir tabaka olusturacak sekilde sürülerek uygulanir. The preferred embodiment of the invention in the form of ointment is in the foot diseases of cattle. It is applied by applying to form a 2-3 mm layer covering the lesion area.
Uygulama öncesinde bölgenin mekanik temizliginin yapilmasi , lezyon üzerinin küretaji, gerekli oldugu durumlarda eksizyonu yapildiktan sonra kullanilmasi bulusun etkinligini arttiracak, kullanim sikligini azaltacaktir. Büyük çapli Iezyonlarda (>2,5 cm) uygulama sonrasi bölgenin pansuman altinda korunmasi iyilesme sürecini olumlu etkilemektedir. Mechanical cleaning of the area before the application, curettage of the lesion, Using it after excision when necessary, increases the effectiveness of the invention. will increase and decrease the frequency of use. Application in large-diameter lesions (>2.5 cm) The protection of the post-operative area under dressing positively affects the healing process.
Pansuman sayisi lezyonun büyüklügüne ve bölgenin dis etkiler ile (idrar ve diski) kirlenmesine bagli olarak degismekle birlikte, büyük Iezyonlarda genellikle 5 gün ara ile yapilmis iki uygulama yeterli oldugu görülmüstür. The number of dressings depends on the size of the lesion and the external effects of the area (urine and disc). Although it varies depending on the contamination, it is usually 5 days apart in large lesions. It has been seen that two applications made are sufficient.
Sigirlar üzerinde gerçeklestirilen ön çalismalarda tedavi süreçleri görüntülenmis ve sekillerde sunulmustur. In the preliminary studies carried out on cattle, the treatment processes were visualized and presented in the figures.
Sekil 1'de örnek olgu olarak akut agrili dermatitis lezyonu üzerinde bulusun uygulama görüntüleri gösterilmistir. Application of the invention on an acute painful dermatitis lesion as an example case in Figure 1 images are shown.
Sekil 2Aida digital dermatitisli olguda sagaltim öncesi görünümü ve Sekil ZBide sagaltim sonrasi 6. günde ilk pansuman sonrasi tam sifa görüntüsü görülmektedir. Figure 2Aida pre-treatment view in a case with digital dermatitis and treatment in Fig. ZB On the 6th day after the first dressing, a full healing image is seen.
Sekil 3A'da bilateral ökçe ve digital dermatitis lezyonlari üzerinin mekanik temizligi, küretaji yapilarak ilaç uygulandiktan ve pansumana alinmasi, Sekil 3B'de ise sonraki 6. günde ilk kontrolü ve tam sifa görüntüleri görülmektedir. Mechanical cleaning and curettage of bilateral heel and digital dermatitis lesions in Figure 3A after the drug is applied and the dressing is taken, in Figure 3B, the first control and full healing images are seen.
Sekil 4A'da uniteral digital dermatitis ve interdigital aralik baslangicindaki dermatitis pansuman kontrolünde tam sifa görüntüleri görülmektedir. Figure 4A: unitary digital dermatitis and dermatitis at the onset of the interdigital space Full healing images are seen in the dressing control.
Sekil 5A'da interdigital dermatitis olgusu sagaltim öncesi görünümü ve Sekil SBSde sagaltim sonrasi 7. gündeki ilk pansuman kontrolünde tam sifa görüntüsü görülmektedir. Pre-treatment view of the case of interdigital dermatitis in Figure 5A and treatment in SBS in Figure 5A In the first dressing control on the 7th day after the surgery, a full healing image is seen.
Yapilan çalismalarda bulusun kullanimi sirasinda klinik gözlemlerde sigirlarda herhangi bir deri reaksiyonu ile karsilasmamistir. Bulusun kullanimi sonrasi sigirlarda sütte kalinti tespit edilmemistir. gerekli oldugu durumlarda eksizyonu yapildiktan sonra kullanilmasi bulusun etkinligini arttiracak, kullanim sikligini azaltacaktir. Büyük çapli Iezyonlarda (>2,5 cm) uygulama sonrasi bölgenin pansuman altinda korunmasi iyilesme sürecini olumlu etkilemektedir. During the use of the invention in the studies performed, no clinical observations were observed in cattle. He did not encounter any skin reaction. Detection of residues in milk in cattle after the use of the invention has not been made. Using it after excision when necessary, increases the effectiveness of the invention. will increase and decrease the frequency of use. Application in large-diameter lesions (>2.5 cm) The protection of the post-operative area under dressing positively affects the healing process.
Pansuman sayisi lezyonun büyüklügüne ve bölgenin dis etkiler ile (idrar ve diski) kirlenmesine bagli olarak degismekle birlikte, büyük Iezyonlarda genellikle 5 gün ara ile yapilmis iki uygulama yeterli oldugu görülmüstür. The number of dressings depends on the size of the lesion and the external effects of the area (urine and disc). Although it varies depending on the contamination, it is usually 5 days apart in large lesions. It has been seen that two applications made are sufficient.
Sigirlar üzerinde gerçeklestirilen ön çalismalarda tedavi süreçleri görüntülenmis ve sekillerde sunulmustur. In the preliminary studies carried out on cattle, the treatment processes were visualized and presented in the figures.
Sekil 1'de örnek olgu olarak akut agrili dermatitis lezyonu üzerinde bulusun uygulama görüntüleri gösterilmistir. Application of the invention on an acute painful dermatitis lesion as an example case in Figure 1 images are shown.
Sekil 2Aida digital dermatitisli olguda sagaltim öncesi görünümü ve Sekil ZBide sagaltim sonrasi 6. günde ilk pansuman sonrasi tam sifa görüntüsü görülmektedir. Figure 2Aida pre-treatment view in a case with digital dermatitis and treatment in Fig. ZB On the 6th day after the first dressing, a full healing image is seen.
Sekil 3A'da bilateral ökçe ve digital dermatitis lezyonlari üzerinin mekanik temizligi, küretaji yapilarak ilaç uygulandiktan ve pansumana alinmasi, Sekil 3B'de ise sonraki 6. günde ilk kontrolü ve tam sifa görüntüleri görülmektedir. Mechanical cleaning and curettage of bilateral heel and digital dermatitis lesions in Figure 3A after the drug is applied and the dressing is taken, in Figure 3B, the first control and full healing images are seen.
Sekil 4A'da uniteral digital dermatitis ve interdigital aralik baslangicindaki dermatitis pansuman kontrolünde tam sifa görüntüleri görülmektedir. Figure 4A: unitary digital dermatitis and dermatitis at the onset of the interdigital space Full healing images are seen in the dressing control.
Sekil 5A'da interdigital dermatitis olgusu sagaltim öncesi görünümü ve Sekil SBSde sagaltim sonrasi 7. gündeki ilk pansuman kontrolünde tam sifa görüntüsü görülmektedir. Pre-treatment view of the case of interdigital dermatitis in Figure 5A and treatment in SBS in Figure 5A In the first dressing control on the 7th day after the surgery, a full healing image is seen.
Yapilan çalismalarda bulusun kullanimi sirasinda klinik gözlemlerde sigirlarda herhangi bir deri reaksiyonu ile karsilasmamistir. Bulusun kullanimi sonrasi sigirlarda sütte kalinti tespit edilmemistir. During the use of the invention in the studies performed, no clinical observations were observed in cattle. He did not encounter any skin reaction. Detection of residues in milk in cattle after the use of the invention has not been made.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2018/07543A TR201807543A2 (en) | 2018-05-28 | 2018-05-28 | Pharmaceutical Composition for the Treatment of Infectious Foot Diseases of Animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2018/07543A TR201807543A2 (en) | 2018-05-28 | 2018-05-28 | Pharmaceutical Composition for the Treatment of Infectious Foot Diseases of Animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201807543A2 true TR201807543A2 (en) | 2018-08-27 |
Family
ID=64559090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/07543A TR201807543A2 (en) | 2018-05-28 | 2018-05-28 | Pharmaceutical Composition for the Treatment of Infectious Foot Diseases of Animals |
Country Status (1)
| Country | Link |
|---|---|
| TR (1) | TR201807543A2 (en) |
-
2018
- 2018-05-28 TR TR2018/07543A patent/TR201807543A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200179300A1 (en) | Topical Formulation Cures and Heals a Variety of Skin Conditions Including Ulcers, Decubitus Ulcers, Cancer, Abrasions and other Conditions and also accelerates the curing and healing of those Conditions | |
| JP7148994B2 (en) | Bisphosphosingel preparation and its use | |
| US20080020025A1 (en) | Composition for wound care and method of using same | |
| JP2016506932A (en) | Compositions and methods for treating surface wounds | |
| KR20170018852A (en) | Topical compositions and methods for treating wounds | |
| WO2012095719A1 (en) | Melatonin and an antimicrobial or antibacterial agent for the treatment of acne | |
| US10561640B2 (en) | Topical preparation for skin tissue protection and reparation | |
| US20140363486A1 (en) | Methods for reducing or altering scar formation | |
| JP2015081244A (en) | Acne treating pharmaceutical composition | |
| PT683670E (en) | WOUND HEALING COMPOSITIONS CONTAINING IODINE AND A REDUCING ACID | |
| TR201807543A2 (en) | Pharmaceutical Composition for the Treatment of Infectious Foot Diseases of Animals | |
| US3920847A (en) | Composition for medical, veterinary of cosmetological use containing a diethyl pyrocarbonate | |
| RU2636523C1 (en) | Drug for wound healing acceleration containing rubidium chloride in powder form | |
| ES2971823T3 (en) | Enhancement of the antibacterial actions of a depsipeptide antibiotic through synergistic amounts of boric acid | |
| EP3976018B1 (en) | Composition for use in the treatment of foot and mouth disease (fmd), scabby mouth (orf), picornavirus, parapoxvirus, and a pathogenic disease causing pox lesions | |
| RU2356556C1 (en) | Medicine for treatment of mammary glands inflammation and traumas in cows | |
| RU2542376C1 (en) | Agent for pyoinflammatory processes in soft tissues and mucous membranes | |
| Shahabaddin et al. | Clinical assessment of four individual treatment for digital dermatitis in dairy cows | |
| RU2268739C2 (en) | Therapeutic gel based on bioactive blood-sucker producing substances and method for production thereof | |
| WO2007143586A2 (en) | Composition for wound care and method of using same | |
| JP3187806B2 (en) | External preparation for treating atopic dermatitis containing nitroimidazole compound | |
| RU2826871C1 (en) | Pharmaceutical composition for treating septic wounds, conjunctivitis, mastitis and endometritis in mammal other than human | |
| WO2012172318A1 (en) | Formulations containing tropolonoids, copper salt and a solvent system | |
| Muhammad et al. | Management of Diffuse Necrotic Cutaneous Wound in a Dog | |
| US20240299618A1 (en) | Means and methods for wound healing |